Literature DB >> 24192655

Self-reported psychotic-like experiences are a poor estimate of clinician-rated attenuated and frank delusions and hallucinations.

Frauke Schultze-Lutter1, Fritz Renner, Julia Paruch, Dominika Julkowski, Joachim Klosterkötter, Stephan Ruhrmann.   

Abstract

BACKGROUND: One reason for the decision to delay the introduction of an Attenuated Psychosis Syndrome in the main text of the fifth edition of the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders was the concern that attenuated psychotic symptoms (APS) might in fact be common features in adolescents and young adults from the general population of no psychopathological significance in themselves. This concern was based on reports of high prevalence rates of psychotic-like experiences (PLEs) in the general population and the assumption that PLEs are a good estimate of APS. Although the criterion validity of self-reported PLEs had already been studied with respect to clinician-rated psychotic symptoms and found insufficient, it had been argued that PLEs might in fact be more comparable with mild, subclinical expressions of psychotic symptoms and, therefore, with APS. The present paper is the first to specifically study this assumption. SAMPLING AND METHODS: The sample consisted of 123 persons seeking help at a service for the early detection of psychosis, of whom 54 had an at-risk mental state or psychosis, 55 had a nonpsychotic mental disorder and 14 had no full-blown mental disorder. PLEs were assessed with the Peters Delusion Inventory and the revised Launay-Slade Hallucination Scale, and psychotic symptoms and APS were assessed with the Structured Interview for Prodromal Syndromes.
RESULTS: At a level of agreement between the presence of any PLE (in 98.4% of patients) and any APS (in 40.7%) just exceeding chance (κ = 0.022), the criterion validity of PLEs for APS was insufficient. Even if additional qualifiers (high agreement or distress, preoccupation and conviction) were considered, PLEs (in 52.8%) still tended to significantly overestimate APS, and agreement was only fair (κ = 0.340). Furthermore, the group effect on PLE prevalence was, at most, moderate (Cramer's V ≤ 0.382).
CONCLUSIONS: The prevalence of APS cannot be deduced from studies of PLEs. Thus, the high population prevalence rate of PLEs does not allow the conclusion that APS are common features of no pathological significance and would lack clinical validity as an Attenuated Psychosis Syndrome in the Diagnostic and Statistical Manual of Mental Disorders, 5th edition. Rather, the population prevalence rate of APS has to be assumed to be largely unknown at present but is likely lower than indicated by epidemiological studies of PLEs. Therefore, dedicated studies are warranted, in which APS are assessed in a way that equates to their clinical evaluation.
© 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2013        PMID: 24192655     DOI: 10.1159/000355554

Source DB:  PubMed          Journal:  Psychopathology        ISSN: 0254-4962            Impact factor:   1.944


  21 in total

1.  What Is an Attenuated Psychotic Symptom? On the Importance of the Context.

Authors:  Paolo Fusar-Poli; Andrea Raballo; Josef Parnas
Journal:  Schizophr Bull       Date:  2017-07-01       Impact factor: 9.306

2.  High time for a paradigm shift in psychiatry.

Authors:  Anita Riecher-Rössler; Erich Studerus
Journal:  World Psychiatry       Date:  2016-06       Impact factor: 49.548

3.  Epistemological error and the illusion of phenomenological continuity.

Authors:  Josef Parnas; Mads Gram Henriksen
Journal:  World Psychiatry       Date:  2016-06       Impact factor: 49.548

Review 4.  Clinical high risk for psychosis in children and adolescents: a systematic review.

Authors:  Jordina Tor; Montserrat Dolz; Anna Sintes; Daniel Muñoz; Marta Pardo; Elena de la Serna; Olga Puig; Gisela Sugranyes; Inmaculada Baeza
Journal:  Eur Child Adolesc Psychiatry       Date:  2017-09-15       Impact factor: 4.785

5.  Psychosis-risk criteria in the general population: frequent misinterpretations and current evidence.

Authors:  Frauke Schultze-Lutter; Joachim Klosterkötter; Wolfgang Gaebel; Stefanie J Schmidt
Journal:  World Psychiatry       Date:  2018-02       Impact factor: 49.548

6.  Psychosis risk screening: Validation of the youth psychosis at-risk questionnaire - brief in a community-derived sample of adolescents.

Authors:  Eduardo Fonseca-Pedrero; Javier Ortuño-Sierra; Edurne Chocarro; Felix Inchausti; Martin Debbané; Julio Bobes
Journal:  Int J Methods Psychiatr Res       Date:  2016-10-27       Impact factor: 4.035

7.  Does hallucination perceptual modality impact psychosis risk?

Authors:  H F Niles; B C Walsh; S W Woods; A R Powers
Journal:  Acta Psychiatr Scand       Date:  2019-08-16       Impact factor: 6.392

8.  Frequency and pattern of childhood symptom onset reported by first episode schizophrenia and clinical high risk youth.

Authors:  Kristen A Woodberry; Rachael A Serur; Sean B Hallinan; Raquelle I Mesholam-Gately; Anthony J Giuliano; Joanne D Wojcik; Matcheri S Keshavan; Jean A Frazier; Jill M Goldstein; Martha E Shenton; Robert W McCarley; Larry J Seidman
Journal:  Schizophr Res       Date:  2014-06-10       Impact factor: 4.939

9.  Comparison of self-report and clinician-rated schizotypal traits in schizotypal personality disorder and community controls.

Authors:  Chi C Chan; Andrea Bulbena-Cabre; Sarah Rutter; Caridad Benavides; Margaret M McClure; William Calabrese; Daniel R Rosell; Harold W Koenigsberg; Marianne Goodman; Antonia S New; Erin A Hazlett; M Mercedes Perez-Rodriguez
Journal:  Schizophr Res       Date:  2019-01-08       Impact factor: 4.939

10.  Depression predicts persistence of paranoia in clinical high-risk patients to psychosis: results of the EPOS project.

Authors:  Raimo K R Salokangas; Frauke Schultze-Lutter; Jarmo Hietala; Markus Heinimaa; Tiina From; Tuula Ilonen; Eliisa Löyttyniemi; Heinrich Graf von Reventlow; Georg Juckel; Don Linszen; Peter Dingemans; Max Birchwood; Paul Patterson; Joachim Klosterkötter; Stephan Ruhrmann
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2015-12-07       Impact factor: 4.328

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.